-
Analyst Opinions
NewUnited Kingdom (UK) Personal Lines Insurance Distribution Dynamics and Future Market, 2023 Update
United Kingdom (UK) Personal Lines Insurance Market Report Overview The direct channel was the preferred choice for personal insurance purchases in the UK in 2023. Consumers are increasingly opting for online insurance purchases driving insurers and distributors to continue enhancing their online capabilities. Consumers prioritize affordability and trustworthiness when selecting an insurance provider, regardless of distribution channel. Hence, across all lines of distribution, the primary factors influencing consumers’ choice is either related to the cost of premiums or the provider’s...
-
Innovation Ranking
NewInnovation Ranking – Prestige International Inc.
Prestige International Inc (Prestige) is a business process outsourcing company. The company offers various services which include roadside assistance for non-life insurance companies, automotive-related services, claim handling services, healthcare programs, and supply chain management solutions. It also provides product extended warranties, customer relationship management service, temporary staffing, information technology-related services, regional revitalization and childcare orangery services. The company provides financial guarantees such as rent guarantees, medical expense guarantees, nursing care expense guarantees, household equipment warranties, and property assistance services. The...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Trastuzumab Biosimilar in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Biosimilar in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trastuzumab Biosimilar in Adenocarcinoma Of The Gastroesophageal Junction...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Trastuzumab Biosimilar in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Biosimilar in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trastuzumab Biosimilar in Gastric Cancer Drug Details: Trastuzumab biosimilar is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Trastuzumab Biosimilar in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Biosimilar in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trastuzumab...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Bevacizumab Biosimilar in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bevacizumab Biosimilar in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bevacizumab Biosimilar in Non-Small Cell Lung Cancer Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LB-100 in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LB-100 in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LB-100 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: LB-100...
-
Product Insights
Retinopathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Retinopathy - Drugs In Development, 2023’, provides an overview of the Retinopathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Retinopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Hemoglobinuria – Drugs In Development, 2023
Global Markets Direct’s, ‘Hemoglobinuria - Drugs In Development, 2023’, provides an overview of the Hemoglobinuria pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemoglobinuria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Paroxysmal Nocturnal Hemoglobinuria – Drugs In Development, 2023
Global Markets Direct’s, ‘Paroxysmal Nocturnal Hemoglobinuria - Drugs In Development, 2023’, provides an overview of the Paroxysmal Nocturnal Hemoglobinuria pipeline landscape. The report provides comprehensive information on the therapeutics under development for Paroxysmal Nocturnal Hemoglobinuria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...